A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
A phase 3 trial of Imlunestrant, Tamoxifen and Exemestane in advanced solid tumours, run by Eli Lilly and Company, active and no longer recruiting.
Overview
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer is a phase 3 interventional study registered as NCT05514054 by Eli Lilly and Company, with 8000 participants enrolled, started 2022-10-04 and due to reach its primary completion in 2027-10. Interventions recorded: Imlunestrant, Tamoxifen, Anastrozole, Letrozole and Exemestane.
Similar pages
not linked directly; found by shared links- TrialA Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Shares Imlunestrant, Tamoxifen, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
Shares Tamoxifen, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Shares Exemestane, Tamoxifen, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialOvarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Shares Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.